| Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) (NCT05165407) | Peking University | 2022-07-12 |
| Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm (NCT05113355) | Peking Union Medical College Hospital | 2021-11-17 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (NCT04750954) | National Cancer Institute (NCI) | 2021-07-22 |
| Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients (NCT06343428) | European Institute of Oncology | 2021-07-19 |
| Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis (NCT04931446) | Xian-Jun Yu | 2021-07-01 |
| Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm (NCT04927611) | Fudan University | 2021-06-06 |
| Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET) (NCT04720391) | European Institute of Oncology | 2021-01-08 |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (NCT04464122) | University of Roma La Sapienza | 2020-09-14 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (NCT04459273) | Jonsson Comprehensive Cancer Center | 2020-08-27 |
| Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients (NCT04917484) | Tine Gregersen, MD | 2020-02-01 |
| Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. (NCT03980925) | Grupo Espanol de Tumores Neuroendocrinos | 2019-10-11 |
| Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (NCT03950609) | M.D. Anderson Cancer Center | 2019-07-30 |
| A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors (NCT03734913) | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | 2019-01-25 |
| Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases (NCT03457948) | Nicholas Fidelman, MD | 2018-08-27 |
| A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms (NCT03511768) | Xiangya Hospital of Central South University | 2018-01-02 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (NCT02831179) | Vanderbilt-Ingram Cancer Center | 2017-12-01 |
| 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors (NCT03001349) | M.D. Anderson Cancer Center | 2017-05-16 |
| Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging (NCT02817945) | Peking Union Medical College Hospital | 2016-06-01 |
| Project: Every Child for Younger Patients With Cancer (NCT02402244) | Children's Oncology Group | 2015-11-03 |
| Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer (NCT02402920) | M.D. Anderson Cancer Center | 2015-07-22 |
| Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors (NCT02399215) | Roswell Park Cancer Institute | 2015-05-15 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |